Literature DB >> 16983705

Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.

Susana Benlloch1, Jose Marcelo Galbis-Caravajal, Concepcion Martín, Jose Sanchez-Paya, Jose Manuel Rodríguez-Paniagua, Santiago Romero, Juan Jose Mafe, Bartomeu Massutí.   

Abstract

BACKGROUND: The objective of this study was to investigate the diagnostic value of methylation profiles for discrimination between malignant and benign pleural effusions. A secondary objective was to examine the concordance of methylation in samples of serum and pleural fluid.
METHODS: The authors used methylation-specific polymerase chain reaction (MSP) analysis to examine the promoter methylation status of 4 genes in patients with pleural effusion: death-associated protein kinase (DAPK), Ras association domain family 1A (RASSF1A), retinoic acid receptor beta (RARbeta), and p16/INK4a. Pleural effusions were collected from 87 patients who had their diagnoses confirmed on cytologic and/or histologic examinations and clinical evolution. Pleural effusions were classified as malignant (n = 53 patients) or benign (n = 34 patients).
RESULTS: Methylation was detected in serum from 45.3% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions, and it was detected in pleural fluid samples from 58.5% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions (P = .001). The sensitivity of MSP was greater than that of cytologic examination alone (39.1%; P = .001). When MSP was used together with cytologic examination, sensitivity increased to 69.8% (P = .001).
CONCLUSIONS: Cell-free methylated DNA in pleural fluid can be detected in patients with neoplastic malignancy in a single extraction by thoracocentesis. Adequate management of the extracted pleural fluid can provide a rapid and reliable diagnosis in patients with pleural effusions who have suspected malignancy. MSP, used together with cytologic examination, may obviate the need for other invasive diagnostic tests. 2006 American Cancer Society

Entities:  

Mesh:

Year:  2006        PMID: 16983705     DOI: 10.1002/cncr.22190

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  DNA methylation as a universal biomarker.

Authors:  Victor V Levenson
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 2.  Malignant pleural effusion and algorithm management.

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Nikolaos Machairiotis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Eirini Terzi; Bojan Zaric; Haidong Huang; Lutz Freitag; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

3.  Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.

Authors:  Maribel Botana-Rial; Loretta De Chiara; Diana Valverde; Virginia Leiro-Fernández; Cristina Represas-Represas; Victor Del Campo-Pérez; Alberto Fernández-Villar
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

4.  Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.

Authors:  Amit Tirosh; Jonathan Keith Killian; David Petersen; Yuelin Jack Zhu; Robert L Walker; Jenny E Blau; Naris Nilubol; Dhaval Patel; Sunita K Agarwal; Lee Scott Weinstein; Paul Meltzer; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

5.  Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura.

Authors:  Grzegorz Kaczmarczyk; Roman Lewandowski; Wanda Trautsolt; Adam Ziółkowski; Jerzy Kozielski
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29

Review 6.  Non-blood circulating tumor DNA detection in cancer.

Authors:  Muyun Peng; Chen Chen; Alicia Hulbert; Malcolm V Brock; Fenglei Yu
Journal:  Oncotarget       Date:  2017-08-04

7.  A Novel Combination of Calprotectin and CXCL12 for Predicting Malignancy in Patients with Exudative Pleural Effusion.

Authors:  Jian Luo; Maoyun Wang; Chuntao Li; Binmiao Liang; Dan Liu; Chaoli Shi; Faming Jiang; Ting Wang; Peijun Li; Zongan Liang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.